James Bogenberger

Translational Cancer Researcher | #PrecisionOncology | #Cholangiocarcinoma | #MyeloidMalignancies

[AML Hub @AML_Hub]

🎥 The AML Hub was pleased to speak with Dr Joshua Zeidner @UNC_Lineberger. He provided an overview of clinical trial data on menin inhibitors for the treatment of NPM1m or KMT2Ar AML, presented at #EHA2025.

Watch the full video here: https://t.co/HC3H8IpsS8

#AMLsm #leusm #MedEd

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

How is this for hope? Is this sustained by MRD-? Time will tell but it’s highly encouraging
#mmsm

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

History in the making at LBA. A phase 3 trial of Daratumumab-VRD vs RVD for TE MM. Superb results with PFS that approximates 85% at4 years
#ASH23RF #mmsm

[Joshua Zeidner MD @LeukDocJZ]

Fantastic presentation by rising star Jake Liu from U of MD reporting on exciting results from a P1 study of Ven + Pegcrisantaspase in R/R AML. Clinical activity in prior Ven and interesting mechanism in RUNX1 mut. 👏👏👏#ASH2023

[Urvi Shah @UrviShahMD]

Congratulations @SBenbarche @AbdelWahablab on your #ASH23 plenary session - Synthetic Introns Identify the Novel RNA Splicing Factor GPATCH8 As Required for Mis-Splicing Induced By SF3B1 Mutations!! @MSKCancerCenter @MSK_DeptOfMed

[Naveen Pemmaraju, MD @doctorpemm]

#ASH23 👉👉👉 Ph3 #TRANSFORM1 randomized , placebo-controlled, double-blinded : Navitoclax + Ruxo vs Ruxo + Placebo ➡️ The Primary Endpoint was met #SVR3524 ➡️ 63.2 % vs 31.5 % SVR at wk24, found to be statistically significant in ITT population | #MPNSM @doctorpemm et al 🙌

[Akshay Sharma MD @AkshaySharmaMD]

📢 Not one but TWO #GeneTherapy products approved for #SickleCell disease by the @US_FDA 👏
Medicine will never be the same again. Now let's make these treatments AFFORDABLE and ACCESSIBLE to all who need them.
https://t.co/LTFOuRfgvd

[Aaron Logan, MD, PhD, MPhil @hemedoc]

#ASH22 #leusm Daver: Frontline data with Pivek/Aza/Ven still early, ORR so far 50%.

[ALL Hub @ALL_Hub_]

CONGRESS| #ASH22
@NitinJainMD, @MDAndersonNews shares safety and preliminary efficacy data from the ongoing phase 1 study of ADCT-602, a CD22 targeting ADC bound to PBD toxin, in adult (≥18 years) pts with R/R B-ALL; well-tolerated overall (one DLT at dose 50µg/kg) #leusm

[Joshua Zeidner MD @LeukDocJZ]

Another fantastic presentation by @Daver_Leukemia reporting on Aza/Ven/Magrolimab in #AML. In the 1L setting, regimen looks promising w/impressive data in TP53 mut. The question is whether Ven adds anything or is it all the Magro in TP53mut? ENHANCE-2/3 enrolling! #ASH22

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Wow. Quite a thread. Calling medications “nonessential” as a way to get payers off the hook. Humira is nonessential? Hemophilia advocates point out the challenges. You have a rare disorder? you are out of luck!

1/x

[Sumanta K. Pal, MD, FASCO @montypal]

Hello to those waking up on the west coast! Had a chance to discuss @DrChoueiri's outstanding presentation of #COSMIC313 at #ESMO22 in the presidential session. Here's a quick synopsis. 1st, what an AMAZING mtg this has been for #kidneycancer (slide credit: @ZeynepZengin) (1/10)

[Myriam Chalabi @MyriamChalabi]

About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot

[Lydia Finley @lydfinley]

Our new work describing a “non-canonical” TCA cycle that is engaged in a cell-state dependent manner is out today in @Nature https://t.co/BqaDhp9YRO. Congratulations to lead authors @paigearnold2 @__btjackson @GSKGradSchool @MSKCancerCenter. A few highlights:

[Hope Rugo @hoperugo]

The data speaks for itself. Destiny breast 04: TDXd beats TDM1 in HER2+MBC. Longest PFS ever in this setting. OS trending better. Low ILD. A new SOC. @myESMO @OncoAlert #ESMO2021 @JavierCortesMD

[ASGCT @ASGCTherapy]

Abstract submission is still open for #IOVC21! This hybrid meeting will bring together clinical, academic, and commercial communities Nov. 5-7 in Sedona, AZ and virtually. Don't miss your chance to get your research in front of your peers! https://t.co/D7aCIF72zz

[James Bogenberger @JM_Bogenberger]

https://t.co/lOWIlMaIn4

[OncLive.com @OncLive]

ICYMI: @US_FDA has granted a breakthrough therapy designation to the combination of venetoclax plus azacitidine for use in the treatment of adult patients with previously untreated, intermediate-, high-, and very high–risk MDS #MDS https://t.co/kmrR7bYHim

[Patrick Cramer @mpgpresident]

PAF and SPT6 stimulate human transcription elongation in distinct ways. Whereas PAF subunit RTF1 stimulates Pol II velocity, SPT6 stimulates Pol II passage through nucleosomes.
Congratulations Kristina Zumer et al.!
https://t.co/PBaKf2Afyn

[Waggoner Lab @LabWaggoner]

Physiologic retrotranscription in human cells. Rna based DNA repair by polymerase theta.
https://t.co/5LvNQSYpnx https://t.co/5LvNQSYpnx